Pfizer plans to charge COVID patients around $1,400 for a five-day course of the antiviral drug Paxlovid. REUTERS. While the US government directly gave funds to Johnson & Johnson and Moderna to ...

Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of ...

Contra. Paxlovid sales in the first three months of 2023 bounced back to surpass analysts’ expectations, with $4.1 billion in sales. Pfizer had previously estimated sales of Paxlovid on the year ...

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year.. A company spokesperson on ...

Pfizer has not disclosed a list price for its Paxlovid pills for once they launch commercially in the U.S. later this year. The company had been selling it in China for reportedly around $292 ...

Pfizer announced on Thursday it has reached an agreement to supply up to six million courses of its COVID-19 antiviral Paxlovid to the Global Fund to get treatment to low and middle-income countries.

In the newly published trial result for Paxlovid, Pfizer showed an 89% reduction in risk of COVID-19-related hospitalization or death among more than 1,200 volunteers, half of whom received a placebo.

Pfizer stands to make a huge amount of money from Paxlovid. The investment bank SVB Leerink estimated that the drug would bring in $24 billion in global revenue in 2022 and $33 billion in 2023.

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can ...

Pfizer will price a course of its Covid-19 drug Paxlovid at nearly $1,400 when commercial sales begin later this year, more than double what the U.S. government has paid.